Logo
x

Search

Subscribe Now

ec approval

Insights+: EMA Marketing Authorization of New Drugs in August 2024

Insights+: EMA Marketing Authorization of New Drugs in August 2024

  • September 24, 2024
Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

  • August 23, 2021
Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

  • July 22, 2021
Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy

Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy

  • July 22, 2021
Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults & Pediatric patients with R/R cHL

Merck's Keytruda (pembrolizumab) Receives the EC's Approval in Adults & Pediatric patients with R/R cHL

  • March 18, 2021
Regeneron’s Libtayo (cemiplimab) Receives EC’s Approval as 1L Treatment of Advanced PD-L1 Positive Non-Small Cell Lung Cancer

    Regeneron’s Libtayo (cemiplimab) Receives EC’s Approval as 1L Treatment of Advanced PD-L1 Positive Non-Small Cell Lung Cancer

    • March 29, 2023
    AstraZeneca and Merck Receive EC’s Approval of Lynparza (olaparib) for Metastatic Castration-Resistant Prostate Cancer

      AstraZeneca and Merck Receive EC’s Approval of Lynparza (olaparib) for Metastatic Castration-Resistant Prostate Cancer

      • December 21, 2022
      AstraZeneca’s Tezspire (tezepelumab) Receives EC’s Approval for the Treatment of Severe Asthma

        AstraZeneca’s Tezspire (tezepelumab) Receives EC’s Approval for the Treatment of Severe Asthma

        • September 21, 2022
        Samsung Bioepis

          Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

          • August 23, 2021
          Bayer and Merck

            Bayer and Merck's Verquvo (vericiguat) Receives the EC's Approval for the Treatment of Chronic Heart Failure

            • July 22, 2021
            Bluebird Bio

              Bluebird Bio's Skysona (elivaldogene autotemcel) Receives EC's Approval for the Treatment of Cerebral Adrenoleukodystrophy

              • July 22, 2021
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.